159 related articles for article (PubMed ID: 36290354)
1. Kinesin Eg5 Selective Inhibition by Newly Synthesized Molecules as an Alternative Approach to Counteract Breast Cancer Progression: An In Vitro Study.
Ricci A; Cataldi A; Carradori S; Zara S
Biology (Basel); 2022 Oct; 11(10):. PubMed ID: 36290354
[TBL] [Abstract][Full Text] [Related]
2. Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
Marconi GD; Carradori S; Ricci A; Guglielmi P; Cataldi A; Zara S
Molecules; 2019 Oct; 24(21):. PubMed ID: 31683688
[TBL] [Abstract][Full Text] [Related]
3. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
De Iuliis F; Taglieri L; Salerno G; Giuffrida A; Milana B; Giantulli S; Carradori S; Silvestri I; Scarpa S
Invest New Drugs; 2016 Aug; 34(4):399-406. PubMed ID: 26994617
[TBL] [Abstract][Full Text] [Related]
4. The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.
Taglieri L; Rubinacci G; Giuffrida A; Carradori S; Scarpa S
Invest New Drugs; 2018 Feb; 36(1):28-35. PubMed ID: 28965307
[TBL] [Abstract][Full Text] [Related]
5. The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells.
Nicolai A; Taurone S; Carradori S; Artico M; Greco A; Costi R; Scarpa S
Invest New Drugs; 2022 Jun; 40(3):556-564. PubMed ID: 35312942
[TBL] [Abstract][Full Text] [Related]
6. Negative Modulation of the Angiogenic Cascade Induced by Allosteric Kinesin Eg5 Inhibitors in a Gastric Adenocarcinoma In Vitro Model.
Ricci A; Gallorini M; Del Bufalo D; Cataldi A; D'Agostino I; Carradori S; Zara S
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164221
[TBL] [Abstract][Full Text] [Related]
7. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
8. Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells.
Giantulli S; De Iuliis F; Taglieri L; Carradori S; Menichelli G; Morrone S; Scarpa S; Silvestri I
Anticancer Drugs; 2018 Aug; 29(7):674-681. PubMed ID: 29738338
[TBL] [Abstract][Full Text] [Related]
9. Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.
Guido BC; Ramos LM; Nolasco DO; Nobrega CC; Andrade BY; Pic-Taylor A; Neto BA; Corrêa JR
BMC Cancer; 2015 Apr; 15():283. PubMed ID: 25885813
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
Talapatra SK; Tham CL; Guglielmi P; Cirilli R; Chandrasekaran B; Karpoormath R; Carradori S; Kozielski F
Eur J Med Chem; 2018 Aug; 156():641-651. PubMed ID: 30031975
[TBL] [Abstract][Full Text] [Related]
11. Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5.
Sun XD; Shi XJ; Sun XO; Luo YG; Wu XJ; Yao CF; Yu HY; Li DW; Liu M; Zhou J
Acta Pharmacol Sin; 2011 Dec; 32(12):1543-8. PubMed ID: 21986572
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
14. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
15. Synthetic studies on mitotic kinesin Eg5 inhibitors: synthesis and structure-activity relationships of novel 2,4,5-substituted-1,3,4-thiadiazoline derivatives.
Yamamoto J; Amishiro N; Kato K; Ohta Y; Ino Y; Araki M; Tsujita T; Okamoto S; Takahashi T; Kusaka H; Akinaga S; Yamashita Y; Nakai R; Murakata C
Bioorg Med Chem Lett; 2014 Aug; 24(16):3961-3. PubMed ID: 25001485
[TBL] [Abstract][Full Text] [Related]
16. Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5.
Exertier P; Javerzat S; Wang B; Franco M; Herbert J; Platonova N; Winandy M; Pujol N; Nivelles O; Ormenese S; Godard V; Becker J; Bicknell R; Pineau R; Wilting J; Bikfalvi A; Hagedorn M
Oncotarget; 2013 Dec; 4(12):2302-16. PubMed ID: 24327603
[TBL] [Abstract][Full Text] [Related]
17. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
18. Protein Phosphatase 2A (PP2A) Regulates EG5 to Control Mitotic Progression.
Liu Y; Zhang Z; Liang H; Zhao X; Liang L; Wang G; Yang J; Jin Y; McNutt MA; Yin Y
Sci Rep; 2017 May; 7(1):1630. PubMed ID: 28487562
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.
Debonis S; Skoufias DA; Indorato RL; Liger F; Marquet B; Laggner C; Joseph B; Kozielski F
J Med Chem; 2008 Mar; 51(5):1115-25. PubMed ID: 18266314
[TBL] [Abstract][Full Text] [Related]
20. A potent chemotherapeutic strategy for bladder cancer: (S)-methoxy-trityl-L-cystein, a novel Eg5 inhibitor.
Ding S; Nishizawa K; Kobayashi T; Oishi S; Lv J; Fujii N; Ogawa O; Nishiyama H
J Urol; 2010 Sep; 184(3):1175-81. PubMed ID: 20663523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
